PharmaJet

Our own Gregg Wilson, Director of Medical and Scientific Affairs at PharmaJet, will be presenting a poster this Friday, November 8, at the Society of Immunotherapy of Cancer (SITC) conference. The poster will focus on how PharmaJet needle-free technology can improve DNA vaccine delivery and how it has been successfully adopted into multiple cancer vaccine development programs. #vaccineswork, #needlefree, #cancertherapeutics https://lnkd.in/gEKi2H_P

PharmaJet is proud to contribute to the polio eradication effort! Needle-free can improve coverage rates, reduce costs, and enable house-to-house campaigns!

We are pleased to announce the results of the implementation study for routine polio immunization with Tropis ID in Nigeria. Compared to the standard of care (full dose needle and syringe IM delivery), Tropis delivered 11.2% higher vaccination coverage with the second dose, up to 47% total immunization cost savings and was preferred by 95% of healthcare workers! Read the news here: https://lnkd.in/gSg5Wc-3

Our Chief Scientific Officer, Nathalie Landry, will be presenting at the upcoming World Vaccine Congress - Europe 2024 on October 29. The presentation entitled "Improving Performance of Vaccines with Needle-free Technology" will highlight the results of recent studies using needle-free delivery across infectious disease, oncology and autoimmune disease indications. Read our news release for more information: https://lnkd.in/gjHqX7Ub

The PharmaJet Team was invited to Addis Ababa, Ethiopia last week to conduct a workshop on novel vaccine delivery with a focus on how needle-free intradermal delivery can harness the full power of the immune system.   We presented the results from a recent USAID-funded study in Nigeria showing how intradermal delivery of IPV with Tropis® ID can expand coverage and reduce total routine immunization costs.   Many thanks to our partner, Etmedix, and to the immunization experts from USAID, CHAI, Ethiopian Medical Association (EMA), Ethiopian Midwives Association (EMWA), Ministry of Health, JSI, PATH, WHO, and Africa CDC who attended the workshop. 

The PharmaJet Team was invited to Addis Ababa, Ethiopia last week to conduct a workshop on novel vaccine delivery with a focus on how needle-free intradermal delivery can harness the full power of the immune system.   We presented the results from a recent USAID-funded study in Nigeria showing how intradermal delivery of IPV with Tropis® ID can expand coverage and reduce total routine immunization costs.   Many thanks to our partner, Etmedix, and to the immunization experts from USAID, CHAI, Ethiopian Medical Association (EMA), Ethiopian Midwives Association (EMWA), Ministry of Health, JSI, PATH, WHO, and Africa CDC who attended the workshop. 

We are pleased to welcome Dr. Wouter Latour who has joined PharmaJet as Chief Executive Officer and as a member of the board of directors. He is a proven biotechnology leader with a distinguished track record in the vaccine and biopharmaceutical industry. https://lnkd.in/d65rWXiQ

On Sept 13, PharmJet and partners (Jhpiego, PATH, Sydani Group, and Nigerian Public Health Development Agency (NPHCDA) met with experts in Abuja to disseminate results from a USAID-funded study conducted in Nigeria. The study results were positive across the board indicating that needle-free delivery of inactivated polio vaccine with Tropis is effective at increasing coverage, decreasing program costs, and is scalable for routine immunization use.   Many thanks to USAID and to our partners for enabling this level of scientific rigor! https://lnkd.in/gfDHhDjj #needlefree, #polio, #vaccinehesitation, #polioeradication, #mpox, #nigeria, #NPHCDA, #USAID

We are pleased to share that PharmaJet and Scancell have signed a strategic partnership agreement for the development and commercialization of a needle-free DNA Vaccine for Advanced Melanoma. This agreement builds on our strategy to be the best-in-class delivery system for novel DNA and RNA cancer immunotherapies. Read the release here: https://lnkd.in/gDJTW9Ab

PharmaJet looks forward to working with Scancell to advance their innovation further through clinical development and commercialization for the ultimate benefit of melanoma patients worldwide!